Chemical Component Summary

Name2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
Identifiers2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
FormulaC14 H7 Cl2 N O3
Molecular Weight308.12
Isomeric SMILESOC(=O)c1ccc2nc(oc2c1)c3cc(Cl)cc(Cl)c3

Chemical Details

Formal Charge0
Atom Count27
Chiral Atom Count0
Bond Count29
Aromatic Bond Count15

Drug Info: DrugBank

DrugBank IDDB11644 
  • approved
  • investigational
DescriptionTafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX.[A189717] Tafamidis is structurally similar to diflusinal.[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
  • Tafamidisum
  • Tafamidis meglumine
  • Tafamidis
Brand Names
  • Vyndaqel
  • Vyndamax
IndicationTafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.[A189708,A189711,L11280]
  • Anti-Inflammatory Agents
  • BCRP/ABCG2 Inhibitors
  • Fused-Ring Compounds
  • Heterocyclic Compounds, Fused-Ring
  • Hormones, Hormone Substitutes, and Hormone Antagonists
CAS number594839-88-0

Drug Targets

NameTarget SequencePharmacological ActionActions
ATP-binding cassette sub-family G member 2MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...unknowninhibitor
Solute carrier family 22 member 6MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR...unknowninhibitor
Solute carrier family 22 member 8MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...unknowninhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682